HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koop, B. L Articles by Ezzat, S. Search for Related Content PubMed Articles by Koop, B. L Articles by Ezzat, S.

Effect of octreotide on glucose tolerance in acromegaly

Koop BL, Harris AG. Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994;130:581–6. ISSN 0804–4643

To determine the effect of the somatostatin analog octreotide on glucose tolerance in acromegaly, we examined glucose profiles, oral glucose tolerance and the insulinogenic index in patients treated with this analog. Ninety patients participated in a long-term, prospective, open-label study. There was no significant change between mean daily blood glucose profiles at baseline or during octreotide treatment. Using glucose tolerance test criteria, 61% of 90 patients had normal baseline glucose tolerance. While on octreotide, 20% and 29% of these patients, respectively, developed impaired glucose tolerance or became frankly diabetic. Conversely, three of the patients who were diabetic at baseline (N = 11) became normal (18%) or developed impaired glucose tolerance (9%) during octreotide therapy. There was no relationship between the dose of octreotide and change in glycemic state. The insulinogenic index (insulin/glucose) response to a glucose challenge decreased uniformly in octreotide-treated patients. Female patients and those with elevated baseline insulin levels were more likely to develop diabetes mellitus during octreotide therapy. In conclusion, octreotide significantly alters glucose tolerance in patients with acromegaly, mandating glucose monitoring during this form of therapy.

Alan G Harris, Division of Clinical Pharmacology, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA

This article has been cited by other articles:

				S. J. C. M. M. Neggers, M. O. van Aken, J. A. M. J. L. Janssen, R. A. Feelders, W. W. de Herder, and A.-J. van der Lely Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4598 - 4601. [Abstract] [Full Text] [PDF]

				R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, and J. O. L. Jorgensen The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1724 - 1728. [Abstract] [Full Text] [PDF]

				J. O. L. Jorgensen, U. Feldt-Rasmussen, J. Frystyk, J.-W. Chen, L. O. Kristensen, C. Hagen, and H. Orskov Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5627 - 5631. [Abstract] [Full Text] [PDF]

				A. Ben-Shlomo and S. Melmed The Role of Pharmacotherapy in Perioperative Management of Patients with Acromegaly J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 963 - 968. [Full Text] [PDF]

				T. O'Connell and D. R. Clemmons IGF-I/IGF-Binding Protein-3 Combination Improves Insulin Resistance By GH-Dependent and Independent Mechanisms J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4356 - 4360. [Abstract] [Full Text] [PDF]

				C. Parkinson, W. M. Drake, M. E. Roberts, K. Meeran, G. M. Besser, and P. J. Trainer A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1797 - 1804. [Abstract] [Full Text] [PDF]

				A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell Sandostatin LAR in Acromegalic Patients: Long Term Treatment J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28. [Abstract] [Full Text] [PDF]